FivepHusion will be attending and presenting at BIO Digital 2021, on June 14-18. As it prepares for its phase III pivotal registration trial, FivepHusion is seeking investment and strategic partners to pursue registration and commercialisation of Deflexifol™ as the new standard of care for solid tumor treatment.
Posts in category Uncategorized
The bridging PK study of Deflexifol is progressing well. Study chief investigator Associate Professor Daniel Brungs reports that patients are being recruited to Dose Level 4. 14 patients have been treated so far. The study appears to reinforce earlier findings about the safety and tolerability of Deflexifol – with patients tolerating 40% higher dosing than […]
The bridging PK study of Deflexifol is reported to be progressing well. Sponsored by Detsamma Investments under an out-license from FivepHusion, the clinical trial is being undertaken at the Southern Medical Day Care Centre in Wollongong, Australia. Study chief investigator Associate Professor Daniel Brungs reports that patients are still being recruited to Dose Level 2, […]
Fivephusion has concluded a drug development partnership deal with Detsamma Investments Pty Ltd. Detsamma will fund the further development of Deflexifol, including completing a bridging trial to gather extra data sought by the FDA. Detsamma Investments plans to complete the bridging trial in 2020, and follow this with a pre-IND meeting with the FDA. Detsamma […]